David Scott, Ph.D., is a Scientific Director at Bioclinica. His aim is to facilitate drug development through standardized measurement of the neural correlates of neurodegenerative and other centrally mediated diseases. As a student at Johns Hopkins University and the University of Michigan, he employed multi-modal imaging approaches including dynamic PET and functional MRI to study the neurobiology of placebo analgesia. At Omneuron, he developed real-time fMRI applications aimed at treating chronic pain, depression and addiction. Since joining Bioclinica in 2012, David’s focus has been to enable MRI and molecular imaging solutions toward safety, eligibility and therapeutic efficacy endpoints. He works with Bioclinica’s staff radiologists, physicists, software engineers, and operational specialists on the design, execution, analysis and interpretation of imaging clinical trials in the neuroscience therapeutic area. His motivation is to effectively translate advanced neuroimaging tools from the lab to the clinic, so that therapeutic benefit can be delivered to patients around the world.